Literature DB >> 1670734

Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding.

J R Laporte1, X Carné, X Vidal, V Moreno, J Juan.   

Abstract

To assess the risk of upper gastrointestinal bleeding associated with the use of individual non-narcotic analgesics and non-steroidal anti-inflammatory drugs (NSAIDs), a multicentre study of 875 cases of upper gastrointestinal bleeding and 2682 hospital controls was done. With control for confounding factors, the overall odds ratio estimate for aspirin taken at least once during the week before the first symptom was 7.2 (95% confidence interval 5.4-9.6). Non-aspirin NSAIDs associated with upper gastrointestinal bleeding were diclofenac (7.9 [4.3-14.6]), indomethacin (4.9 [2.0-12.2]), naproxen (6.5 [2.2-19.6]), and piroxicam (19.1 [8.2-44.3]). Paracetamol, propyphenazone, and dipyrone did not increase the risk. A previous history of gastrointestinal bleeding or peptic ulcer did not greatly affect odds ratio estimates, which differed according to sex and were higher for younger than for older patients. However, the incidence of upper gastrointestinal bleeding was higher among the elderly.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1670734     DOI: 10.1016/0140-6736(91)90744-a

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  61 in total

1.  Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials.

Authors:  G Leandro; A Pilotto; M Franceschi; T Bertin; E Lichino; F Di Mario
Journal:  Dig Dis Sci       Date:  2001-09       Impact factor: 3.199

Review 2.  Gastrointestinal complications of nonsteroidal anti-inflammatory drugs.

Authors:  R R Babb
Journal:  West J Med       Date:  1992-10

Review 3.  [Non-opioid analgesics for perioperative pain therapy. Risks and rational basis for use].

Authors:  A Brack; H L Rittner; M Schäfer
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

Review 4.  Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs?

Authors:  K Bloor; A Maynard
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

5.  Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database.

Authors:  S Lugardon; M Lapeyre-Mestre; J L Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2004-10-23       Impact factor: 2.953

6.  Spontaneous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report from the Spanish System of Pharmacovigilance, including an early analysis of topical and enteric-coated formulations.

Authors:  A Figueras; D Capellà; J M Castel; J R Laorte
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data.

Authors:  S C Lewis; M J S Langman; Joan-Ramon Laporte; John N S Matthews; Michael D Rawlins; Bengt-Erik Wiholm
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

Review 8.  [New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase].

Authors:  D O Stichtenoth; H Zeidler; J C Frölich
Journal:  Med Klin (Munich)       Date:  1998-07-15

9.  NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies.

Authors:  Alberto Pilotto; Marilisa Franceschi; Gioacchino Leandro; Francesco Di Mario
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Perception of the risk of gastrointestinal adverse drug reactions with non-steroidal anti-inflammatory drugs (including coxibs): differences among general practitioners, gastroenterologists and rheumatologists.

Authors:  J L Montastuc; V Bongard; M Lapeyre-Mestre
Journal:  Eur J Clin Pharmacol       Date:  2003-10-11       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.